Cargando…

APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus

BACKGROUND: Systemic lupus erythematosus (SLE) disproportionately affects individuals of African ancestry (AA) compared to European ancestry (EA). In the general population, high risk (HR) variants in the apolipoprotein L1 (APOL1) gene increase the risk of renal and hypertensive disorders in individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Cecilia P, Karakoc, Gul, Dickson, Alyson, Liu, Ge, Gamboa, Jorge L, Mosley, Jonathan D, Cox, Nancy J, Kawai, Vivian K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189827/
https://www.ncbi.nlm.nih.gov/pubmed/37105192
http://dx.doi.org/10.1177/09612033231172660
_version_ 1785043166477418496
author Chung, Cecilia P
Karakoc, Gul
Dickson, Alyson
Liu, Ge
Gamboa, Jorge L
Mosley, Jonathan D
Cox, Nancy J
Kawai, Vivian K
author_facet Chung, Cecilia P
Karakoc, Gul
Dickson, Alyson
Liu, Ge
Gamboa, Jorge L
Mosley, Jonathan D
Cox, Nancy J
Kawai, Vivian K
author_sort Chung, Cecilia P
collection PubMed
description BACKGROUND: Systemic lupus erythematosus (SLE) disproportionately affects individuals of African ancestry (AA) compared to European ancestry (EA). In the general population, high risk (HR) variants in the apolipoprotein L1 (APOL1) gene increase the risk of renal and hypertensive disorders in individuals of AA. Since SLE is characterized by an interferon signature and APOL1 expression is driven by interferon, we examined the hypothesis that APOL1 HR genotypes predominantly drive higher rates of renal and hypertensive-related comorbidities observed in SLE patients of AA versus those of EA. METHODS: We performed a retrospective cohort study in patients with SLE of EA and AA using a genetic biobank linked to de-identified electronic health records. APOL1 HR genotypes were defined as G1/G1, G2/G2, or G1/G2 and low risk (LR) genotypes as 1 or 0 copies of the G1 and G2 alleles. To identify renal and hypertensive-related disorders that differed in prevalence by ancestry, we used a phenome-wide association approach. We then used logistic regression to compare the prevalence of renal and hypertensive-related disorders in EA and AA patients, both including and excluding patients with the APOL1 HR genotype. In a sensitivity analysis, we examined the association of end stage renal disease secondary to lupus nephritis (LN-related ESRD) with ancestry and the APOL1 genotype. RESULTS: We studied 784 patients with SLE; 195 (24.9%) were of AA, of whom 27 (13.8%) had APOL1 HR genotypes. Eighteen renal and hypertensive-related phenotypes were more common in AA than EA patients (p-value ≤ 1.4E-4). All phenotypes remained significantly different after exclusion of patients with APOL1 HR genotypes, and most point odds ratios (ORs) decreased only slightly. Even among ORs with the greatest decrease, risk for AA patients without the APOL1 HR genotype remained significantly elevated compared to EA patients. In the sensitivity analysis, LN-related ESRD was more prevalent in SLE patients of AA versus EA and AA patients with the APOL1 HR genotype versus LR (p-value < .05 for both). CONCLUSION: The higher prevalence of renal and hypertensive disorders in SLE patients of AA compared to those of EA is not fully explained by the presence of APOL1 high risk variants.
format Online
Article
Text
id pubmed-10189827
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101898272023-05-18 APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus Chung, Cecilia P Karakoc, Gul Dickson, Alyson Liu, Ge Gamboa, Jorge L Mosley, Jonathan D Cox, Nancy J Kawai, Vivian K Lupus Papers BACKGROUND: Systemic lupus erythematosus (SLE) disproportionately affects individuals of African ancestry (AA) compared to European ancestry (EA). In the general population, high risk (HR) variants in the apolipoprotein L1 (APOL1) gene increase the risk of renal and hypertensive disorders in individuals of AA. Since SLE is characterized by an interferon signature and APOL1 expression is driven by interferon, we examined the hypothesis that APOL1 HR genotypes predominantly drive higher rates of renal and hypertensive-related comorbidities observed in SLE patients of AA versus those of EA. METHODS: We performed a retrospective cohort study in patients with SLE of EA and AA using a genetic biobank linked to de-identified electronic health records. APOL1 HR genotypes were defined as G1/G1, G2/G2, or G1/G2 and low risk (LR) genotypes as 1 or 0 copies of the G1 and G2 alleles. To identify renal and hypertensive-related disorders that differed in prevalence by ancestry, we used a phenome-wide association approach. We then used logistic regression to compare the prevalence of renal and hypertensive-related disorders in EA and AA patients, both including and excluding patients with the APOL1 HR genotype. In a sensitivity analysis, we examined the association of end stage renal disease secondary to lupus nephritis (LN-related ESRD) with ancestry and the APOL1 genotype. RESULTS: We studied 784 patients with SLE; 195 (24.9%) were of AA, of whom 27 (13.8%) had APOL1 HR genotypes. Eighteen renal and hypertensive-related phenotypes were more common in AA than EA patients (p-value ≤ 1.4E-4). All phenotypes remained significantly different after exclusion of patients with APOL1 HR genotypes, and most point odds ratios (ORs) decreased only slightly. Even among ORs with the greatest decrease, risk for AA patients without the APOL1 HR genotype remained significantly elevated compared to EA patients. In the sensitivity analysis, LN-related ESRD was more prevalent in SLE patients of AA versus EA and AA patients with the APOL1 HR genotype versus LR (p-value < .05 for both). CONCLUSION: The higher prevalence of renal and hypertensive disorders in SLE patients of AA compared to those of EA is not fully explained by the presence of APOL1 high risk variants. SAGE Publications 2023-04-27 2023-05 /pmc/articles/PMC10189827/ /pubmed/37105192 http://dx.doi.org/10.1177/09612033231172660 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Papers
Chung, Cecilia P
Karakoc, Gul
Dickson, Alyson
Liu, Ge
Gamboa, Jorge L
Mosley, Jonathan D
Cox, Nancy J
Kawai, Vivian K
APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus
title APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus
title_full APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus
title_fullStr APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus
title_full_unstemmed APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus
title_short APOL1 and the risk of adverse renal outcomes in patients of African ancestry with systemic lupus erythematosus
title_sort apol1 and the risk of adverse renal outcomes in patients of african ancestry with systemic lupus erythematosus
topic Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189827/
https://www.ncbi.nlm.nih.gov/pubmed/37105192
http://dx.doi.org/10.1177/09612033231172660
work_keys_str_mv AT chungceciliap apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus
AT karakocgul apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus
AT dicksonalyson apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus
AT liuge apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus
AT gamboajorgel apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus
AT mosleyjonathand apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus
AT coxnancyj apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus
AT kawaiviviank apol1andtheriskofadverserenaloutcomesinpatientsofafricanancestrywithsystemiclupuserythematosus